The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Novartis to pay EUR95m to Galapagos and MorphoSys for skin drug rights.....           Kite, Gadeta collaborate to advance gamma delta T cell receptor technology for solid tumors.....           WuXi STA, Antengene sign drug development and manufacturing deal.....           Is Roche's latest Tecentriq win really a win for Merck's Keytruda?.....           Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali.....           Pfizer, Lilly?s osteoarthritis pain drug meets co-primary endpoints in phase 3 study.....           Takeda, Ovid plan to launch three trials of anti-epileptic drug TAK-935/OV935.....           FDA accepts Immunomedics? BLA and grants priority review for Sacituzumab Govitecan to treat metastatic triple-negative breast cancer.....           EUSA Pharma to buy global rights of Janssen?s Sylvant for $115m.....           Roche?s baloxavir marboxil succeeds in phase III flu study.....           Evoke Group?s expansion drive continues with West Coast agency buy.....           Eisai obesity drug Belviq may have an edge with new heart-safety data?but to what end?.....           Under scrutiny for Cohen deal, Novartis calls off further price hikes in 2018.....           Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough.....           FDA nails Baxter with warning letter for plant picked up in Claris buyout.....           Roche?s baloxavir marboxil reduces flu symptoms in phase III Capstone-2 study.....           Clinigen acquires global rights to Proleukin outside US.....           Eureka Therapeutics announces Boehringer Ingelheim is exercising option to license novel TCRm) antibodies.....           Indivior wins US court order blocking Dr. Reddy's sale of generic opioid treatment.....           Moderna opens $110M manufacturing site for its mRNA program.....           Johnson & Johnson softens FDA's Invokana blow with positive kidney results.....           Winning Trump?s praise was easy for Pfizer. Wall Street and the Hill? Not so much.....           Johnson & Johnson predicts 4% to 6% net price decline in pharma this year, with Remicade down by double digits in Q2.....           Vertex says it's glad England made another offer for CF drugs, but it'll have to do better.....           Indivior wins US court order blocking Dr. Reddy's sale of generic opioid treatment.....           Pfizer begins pivotal phase 3 program for investigational hemophilia B gene therapy.....           Ironwood Pharmaceuticals starts Phase IIIb study of linaclotide in adult patients with IBS-C.....           Ogilvy CommonHealth?s North America CEO snags new chief creative officer.....           Pfizer halts production at India injectables plant after FDA again finds issues.....           FDA joins EU in seeking recall of certain Chinese-made valsartan products over potential cancer risk.....           FDA looks at incentives, manufacturing ?interventions? to solve drug shortages.....           With FDA nod, Pfizer and Astellas? Xtandi gets its shot at blockbuster sales boost.....           Will Mylan?s big Copaxone price break force Teva?s hand? Clients are pushing already.....           Purdue defends against opioid lawsuits by pointing to FDA regulations it helped create.....           Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?.....           SIGA Technologies gets FDA nod for TPOXX to treat smallpox.....           Apotex to divest European generics business.....           Taiho Pharmaceutical exercises option to develop AB928 in its territories.....           Bayer works to connect brand to products with all-American TV ad.....           Hemophilia, the musical: BioMarin sponsors one-of-a-kind performance created by teens.....           McCann Health fires chief creative officer over conduct code violation.....           FiercePharmaAsia?Biogen-Eisai Alzheimer?s win, Otsuka deals, Samsung BioLogics criminal probe.....           High-stakes talc trial ends in whopping $4.7B verdict for Johnson & Johnson.....           MS patent win boosts Novartis? Gilenya, helps Celgene and maybe Biogen too.....           As U.S. trade war escalates, China rolls out red carpet for Indian drugmakers.....           Adempas maker Bayer connects hypertension patients with new mentoring group.....           Senators challenge Novartis' account of Cohen deal, calling it 'longer and more detailed' than disclosed.....           Genmab, Immatics to develop next-generation bispecific cancer immunotherapies.....           Dermavant to buy rights to tapinarof from GSK for £250m.....           Genentech seeks FDA approval for Venclexta for AML.....           Samsung BioLogics to face criminal probe over accounting violation for biosims JV.....           Samsung BioLogics to face criminal probe over accounting fraud for biosims JV.....           Johnson & Johnson enlists diabetes veteran Merck KGaA to hawk Invokana in China.....           Sen. Wyden probes 'secret, sweetheart' deal between Pfizer, Trump.....           Can Mylan dodge Pfizer's Remicade woes with a low-priced Neulasta copy?.....           Otsuka Pharmaceutical to buy biotechnology firm Visterra for $430m.....           AbbVie?s blood cancer drug Ibrutinib fails in phase 3 DLBCL trial.....           FDA grants priority review to Merck?s sBLA for Keytruda to treat advanced hepatocellular carcinoma.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

Donít forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 September 2018 - AstraZeneca, Granta Park, Cambridge
The APS is pleased to announce this exciting 2 day meeting to review the progress and advances made by the collaborative IMI OrBiTo project . The OrBiTo project started in October 2012 and following a twelve-month non-cost extension phase will finish in October 2018.
To learn more and to register, click here

Industrial Insights 2019
Developability for Biologicals
Inhaled Workshop
3D Printing meeting
Basic Biopharmaceutics workshop 

Follow us
Upcoming Events
7 September 2018
"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 - 18 September 2018
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email:

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.